The clinical trial for QT-019C, a universal allogeneic CAR T-cell therapy targeting CD19 and BCMA, is positioned to address significant unmet needs in the treatment of relapse/refractory autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, and connective tissue disease-associated thrombocytopenia. The trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China, with collaboration from Shanghai Xiniao Biotech Co., Ltd. Given the increasing prevalence of autoimmune diseases and the limitations of current therapies, QT-019C could capture a substantial market share if proven effective. However, the competitive landscape includes established therapies and emerging biologics, necessitating robust efficacy and safety data to differentiate QT-019C. The trial is currently recruiting, with an estimated completion date in January 2029, indicating a long-term investment horizon for stakeholders.